.png){kind=logo}
COMPANION ANIMALS
The Problem: Antibiotics Are Failing
-
Multidrug-resistant (MDR) strains of E. coli, Salmonella, and Staphylococcus aureus are increasingly reported in pets. Recent studies confirm resistance levels to common antibiotics like tetracycline, cephalosporins, and ciprofloxacin can exceed 50% in some regions.
-
Overuse of antibiotics perpetuates antimicrobial resistance (AMR), making standard infections harder to treat.
-
Transmission of AMR bacteria between pets and their owners magnifies the crisis.
Zoonotic Risk
-
Direct and indirect transfer is possible.
-
Owners can catch MRSA from infected animals, especially through open wounds or poor hygiene. Human infections are challenging to treat and may become serious or recurrent, creating a cycle of infection in households.
-
These bacteria don’t just endanger your pets, they put your entire household at risk.
-
Children, elderly, and immunocompromised individuals face the greatest danger.
-
Ignoring routine hygiene, food safety, and veterinary care can turn your beloved pet into a source of serious human illness
The real cost of antibiotic failure isn’t the drug - it’s the loss of time, trust, and reputation
.png)
INNOVA AMP PET is a next-generation peptide-based formulation developed for integration into companion animal management programs.
Powered by nano-encapsulated peptide technology, it is designed for use within structured veterinary and nutritional frameworks in environments where bacterial challenges are subject to clinical assessment and regulatory oversight.
Developed to align with responsible production and stewardship principles within modern veterinary practice.